Matthew L Sherman

This inventor holds 13 USPTO granted patents and 28 published patent applications, plus 6 CIPO patents and 11 EPO patents. Top assignees: Acceleron Pharma Inc., Genetics Institute, Inc., Wyeth. Active years: 2002-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Matthew L Sherman. Retrieved from https://idiyas.com/inventor/matthew-l-sherman

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 13 (Patent Applications = 28)

% Patents Active = 92.3

CIPO Patents = 6 (Patent Applications = 11)

EPO Patents = 11 (Patent Applications = 21)

Average Co-Inventor Count = 2.1

ph-index = 9

Forward Citations = 379(Granted Patents)

Company Filing History:

10 out of 172

Acceleron Pharma Inc.

patents

1 out of 392

Genetics Institute, Inc.

4. 1 out of 834,453

Other

patents

Years Active: 2002-2022

Loading Chart...

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11524990 - Methods for treating vascular eye disorders with ActRII antagonists (2022-12-13),

2. 10550170 - Methods for treating vascular eye disorders with actrii antagonists (2020-02-04),

3. 10093707 - Antagonists of activin-ActRIIa and uses for increasing red blood cell levels (2018-10-09),

4. 9919030 - Follistatin fusion proteins and uses thereof (2018-03-20),

5. 9353356 - Activin-actriia antagonists for treating a follicle-stimulating horomone-secreting pituitary tumor (2016-05-31),

6. 8895016 - Antagonists of activin-actriia and uses for increasing red blood cell levels (2014-11-25),

7. 8367611 - Activin-actriia antagonists for inhibiting germ cell maturation (2013-02-05),

8. 8007809 - Activin-actrii antagonists and uses for increasing red blood cell levels (2011-08-30),

9. 7988973 - Activin-ActRII antagonists and uses for increasing red blood cell levels (2011-08-02),

10. 7960343 - Activin-ActRIIa antagonists and uses for decreasing or inhibiting FSH secretion (2011-06-14),

11. 7727968 - Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome (2010-06-01),

12. 6509321 - Treatment of Kaposi's sarcoma with IL-12 (2003-01-21),

13. 6423308 - Treatment of Kaposi's sarcoma with IL-12 (2002-07-23),

Title: Innovations by Matthew L Sherman

Introduction

Matthew L Sherman is a notable inventor based in Newton, MA (US). He has made significant contributions to the field of medical treatments, particularly in the area of eye disorders. With a total of 13 patents to his name, Sherman has demonstrated a commitment to advancing healthcare through innovative solutions.

Latest Patents

Among his latest patents are methods for treating vascular eye disorders with ActRII antagonists. These patents disclose compositions and methods aimed at increasing visual acuity in patients who require such interventions. The focus on treating vascular disorders of the eye highlights Sherman's dedication to improving patient outcomes in ophthalmology.

Career Highlights

Sherman has worked with Acceleron Pharma Inc., where he has likely contributed to the development of groundbreaking therapies. His experience in the pharmaceutical industry has provided him with a platform to translate his innovative ideas into practical applications that benefit patients.

Collaborations

Throughout his career, Sherman has collaborated with esteemed colleagues such as Jasbir S Seehra and John L Knopf. These partnerships have likely enriched his work and expanded the impact of his inventions.

Conclusion

Matthew L Sherman is a distinguished inventor whose work in treating vascular eye disorders has the potential to transform patient care. His numerous patents and collaborations reflect his dedication to innovation in the medical field.

Profile summary based on public USPTO records.